Skip to content

Innovative Insulin Injection Sites Map to Minimize Lipohypertrophy Risk

Strategy for Minimize the Risk for Insulin Induced Lipohypertrophy and Its Related Consequences: Innovative Insulin Injection Sites Map

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07561086
Enrollment
170
Registered
2026-05-01
Start date
2025-06-01
Completion date
2026-01-30
Last updated
2026-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lipohypertrophy, Type 1 Diabetes Mellitus

Keywords

Lipohypertrophy, Patient Education, Randomized Controlled Trial, Diabetes Mellitus

Brief summary

Background: Patients on long-term insulin therapy frequently develop a condition called lipohypertrophy (LH), which involves the accumulation of abnormal fatty tissue at insulin injection sites. This condition is caused by repeated injections in the same area and can lead to inconsistent insulin absorption, unpredictable blood sugar levels, and increased risks of hypoglycemia and hyperglycemia. While standard care often includes verbal instructions on site rotation, many patients continue to struggle with technique and develop these complications. Study Purpose: This study aims to evaluate the effectiveness of a novel "Insulin Injection Sites Map" (provided in either digital or physical format) compared to standard verbal care. The study seeks to determine if this structured, visual mapping tool helps patients better manage their injection rotation, reduces the occurrence and severity of lipohypertrophy, and ultimately improves glycemic control (as measured by HbA1c and fasting blood glucose). Study Design: This is a prospective, randomized controlled trial (RCT) conducted at the outpatient medical clinic of Matrouh General Hospital. The study includes adult participants (aged 18 and older) diagnosed with Type 1 or Type 2 diabetes who have been using insulin therapy for at least six months. Participants are divided into two groups: Intervention Group: Patients who receive the novel structured insulin injection sites map and instructions on systematic rotation. Control Group: Patients who receive routine care, consisting of standard verbal instructions on site rotation without visual mapping aids. Outcome Measures: Over a six-month follow-up period, the study monitors and compares both groups on the following key metrics: Incidence and Severity of Lipohypertrophy: Evaluated through physical inspection and palpation of injection sites for lumps, firmness, or tenderness. Adherence to Rotation Protocols: Measured using patient logs and site rotation scores to determine if participants are following the recommended rotation sequence. Glycemic Control: Tracked through clinical monitoring of HbA1c percentages and fasting blood glucose levels to assess the impact of better injection technique on overall diabetes management.

Interventions

BEHAVIORALInsulin Injection Site Mapping Tool

Participants receive an evidence-based insulin injection site mapping tool designed to guide systematic rotation of insulin injection sites and reduce the risk of insulin-induced lipohypertrophy. The intervention is supported by structured education and follow-up reinforcement.

Sponsors

Helwan University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Masking description

This study is an open-label randomized controlled trial. No masking is applied to participants, care providers, or investigators due to the nature of the intervention. Participants and care providers are aware of group allocation. Participants in the intervention group receive an evidence-based insulin injection site mapping tool, while participants in the control group receive standard verbal instructions on insulin injection technique. Outcome assessment is intended to be conducted independently to minimize measurement bias; however, no additional formal blinding procedures are implemented. The open-label design is appropriate given the educational and behavioral nature of the intervention, which requires active participant engagement and provider instruction to improve adherence to correct insulin injection practices and reduce the risk of lipohypertrophy.

Intervention model description

This study is designed as a parallel-group randomized controlled trial. Participants are randomly assigned in an allocation ratio to either the intervention group or the control group. The study compares the effects of an evidence-based insulin injection site mapping tool versus standard care on preventing insulin-induced lipohypertrophy and improving related clinical outcomes. The intervention group receives a structured insulin injection site mapping tool that includes standardized visual diagrams and written guidance to support systematic rotation of injection sites, along with brief educational reinforcement to improve adherence to the protocol. The control group receives routine clinical care, consisting of standard verbal instructions regarding insulin injection site rotation without the use of structured visual mapping or additional educational reinforcement. Both groups are followed over a six-month period to evaluate differences in clinical outcomes, including the inciden

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adults aged 18 years and older. * Diagnosed with Type 1 or Type 2 diabetes mellitus. * Currently receiving insulin therapy for a minimum of six months. * Capable of self-injecting insulin or receiving assistance with injections at least once daily. * Able and willing to provide informed consent to participate in the study. * Able to understand and follow the study protocols.

Exclusion criteria

* Presence of mental illnesses or severe cognitive impairment that may affect participation. * Individuals with skin disorders at injection sites (e.g., severe eczema, psoriasis, or infections) that could interfere with the evaluation of lipohypertrophy. * Women who are pregnant or lactating. * Participation in another interventional clinical trial within the past three months.

Design outcomes

Primary

MeasureTime frameDescription
Incidence of Insulin-Induced LipohypertrophyBaseline, 3 months, and 6 months post-interventionDescription: The primary outcome is the incidence of insulin-induced lipohypertrophy at injection sites, assessed by trained clinical evaluation using visual inspection and palpation.
Adherence to Insulin Injection Site RotationBaseline, 3 months, and 6 monthsAssessment of participant adherence to recommended insulin injection site rotation protocol.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 8, 2026